镜头：批准是基于P-III ASCLEPIOS Iand II studies that involve assessing Kesimpta (20mg, monthly, SC) vs teriflunomide (14mg, PO, qd) in 1,882 adults aged 18-55yrs. with a confirmed diagnosis of RMS The study demonstrated a reduction of annual relapses by over 50% and achieved >3MOS的相对风险减少30％。确认的 […]阅读更多
